ATE375154T1 - Pharmazeutische verwendung von cox-2-hemmern in angiogenese-vermittelten augenerkrankungen - Google Patents

Pharmazeutische verwendung von cox-2-hemmern in angiogenese-vermittelten augenerkrankungen

Info

Publication number
ATE375154T1
ATE375154T1 AT03731699T AT03731699T ATE375154T1 AT E375154 T1 ATE375154 T1 AT E375154T1 AT 03731699 T AT03731699 T AT 03731699T AT 03731699 T AT03731699 T AT 03731699T AT E375154 T1 ATE375154 T1 AT E375154T1
Authority
AT
Austria
Prior art keywords
cox
angiogenesis
inhibitors
pharmaceutical use
eye diseases
Prior art date
Application number
AT03731699T
Other languages
English (en)
Inventor
Romulus Brazzell
George Lambrou
Elisabeth Latour
Anna Ottlecz
Jeanette Wood
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE375154T1 publication Critical patent/ATE375154T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT03731699T 2002-01-23 2003-01-22 Pharmazeutische verwendung von cox-2-hemmern in angiogenese-vermittelten augenerkrankungen ATE375154T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0201520.4A GB0201520D0 (en) 2002-01-23 2002-01-23 Pharmaceutical uses

Publications (1)

Publication Number Publication Date
ATE375154T1 true ATE375154T1 (de) 2007-10-15

Family

ID=9929598

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03731699T ATE375154T1 (de) 2002-01-23 2003-01-22 Pharmazeutische verwendung von cox-2-hemmern in angiogenese-vermittelten augenerkrankungen

Country Status (17)

Country Link
US (3) US20050043410A1 (de)
EP (1) EP1503746B1 (de)
JP (1) JP2005515241A (de)
CN (1) CN1283240C (de)
AR (1) AR038198A1 (de)
AT (1) ATE375154T1 (de)
BR (1) BR0307013A (de)
CA (1) CA2468811C (de)
CY (1) CY1106994T1 (de)
DE (1) DE60316792T2 (de)
DK (1) DK1503746T3 (de)
ES (1) ES2291641T3 (de)
GB (1) GB0201520D0 (de)
MY (1) MY145266A (de)
PT (1) PT1503746E (de)
TW (1) TWI280878B (de)
WO (1) WO2003061645A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
WO2005049014A1 (en) * 2003-11-18 2005-06-02 Pharmacia Corporation Cox-2 inhibitors for the treatment or prevention of diabetes-related ocular disorders
CN102149728B (zh) * 2008-09-10 2014-10-15 霍夫曼-拉罗奇有限公司 抑制眼部血管生成的方法
WO2010132634A1 (en) * 2009-05-15 2010-11-18 Glaxosmithkline Llc Using thermal imaging for control of a manufacturing process
WO2019070917A1 (en) * 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
CN114652826B (zh) * 2022-01-24 2022-10-14 景泽生物医药(合肥)有限公司 抗egfr抗体的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652762A (en) * 1970-04-14 1972-03-28 Ciba Geigy Corp Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
HRP20010582A2 (en) * 1999-12-08 2002-08-31 Pharmacia Corp Valdecoxib compositions
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
US20030114527A1 (en) * 2001-08-31 2003-06-19 Karnachi Anees Abdulquadar Pharmaceutical composition
EP1467714A1 (de) * 2002-01-07 2004-10-20 Pharmacia Corporation Wirkstoffmischung mit erhöhter auflösungsgeschwindigkeit

Also Published As

Publication number Publication date
US20090247638A1 (en) 2009-10-01
ES2291641T3 (es) 2008-03-01
CA2468811C (en) 2011-08-09
US20050043410A1 (en) 2005-02-24
CA2468811A1 (en) 2003-07-31
CN1620288A (zh) 2005-05-25
TW200302081A (en) 2003-08-01
WO2003061645A1 (en) 2003-07-31
US20120322874A1 (en) 2012-12-20
MY145266A (en) 2012-01-13
AR038198A1 (es) 2005-01-05
DE60316792T2 (de) 2008-07-24
CY1106994T1 (el) 2012-09-26
CN1283240C (zh) 2006-11-08
BR0307013A (pt) 2004-11-03
EP1503746B1 (de) 2007-10-10
JP2005515241A (ja) 2005-05-26
DK1503746T3 (da) 2008-02-04
TWI280878B (en) 2007-05-11
PT1503746E (pt) 2008-01-10
EP1503746A1 (de) 2005-02-09
DE60316792D1 (de) 2007-11-22
GB0201520D0 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
DE60201859D1 (de) Pharmazeutische Verwendung von N-Carbamoylazol-Derivate
CY2016046I1 (el) Κιναζολινονες ως αναστολεις της ανθρωπινης 3-κινασης δελτα της φωσφατιδυλινοσιτολης
DE60315892D1 (de) Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
DK1542748T3 (da) Engangssprøjte
MA29067B1 (fr) Protéines de fusion de RAGE et méthodes d'utilisation
DE60324099D1 (de) Arzneistoffhaltiger tampon
ATE551322T1 (de) 3-z-1-(4-(n-((4-methylpiperazin-1- yl)methylcarbonyl)-n-methylamino)anilino)1- phenylmethylen-6-methoxycarbonyl-2- indolinonmonoethansulfonat und dessen verwendung als pharmazeutische zusammensetzung
DE60322665D1 (de) Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
FR2867962B1 (fr) Plaque d'osteosynthese et spherique
EP1513825A4 (de) Antituberkulöses arzneimittel: zusammensetzungen und verfahren
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
DE60312780D1 (de) Wegwerfwindel
DE50310980D1 (de) VERWENDUNG VON I kappa B-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE
DE60325967D1 (de) Stimulierung von hämatopoiese bei ex vivo aktivierten immunzellen
ATE401891T1 (de) Verwendung von meloxicam-formulierungen in der veterinärmedizin
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
ATE375154T1 (de) Pharmazeutische verwendung von cox-2-hemmern in angiogenese-vermittelten augenerkrankungen
NO20035331D0 (no) Nye heterocyklisk forbindelse og medisinsk anvendelse derav
DE602004022169D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
ATE494278T1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
DE60328787D1 (de) Pharmazeutische salze von reboxetin
DK1680405T3 (da) Bengamidderivater og deres anvendelse til behandling af kræftsygdomme
ATE349213T1 (de) Nasale pharmazeutische zusammensetzung von piribedil
ATE456573T1 (de) Nmb0928-protein und dessen verwendung in pharmazeutischen formulierungen
DE60326437D1 (de) Therapeutische verwendung von sapogeninen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1503746

Country of ref document: EP